Comparative Pharmacology
Head-to-head clinical analysis: MIDAMOR versus TRIAMTERENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAMOR versus TRIAMTERENE.
MIDAMOR vs TRIAMTERENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, reducing sodium reabsorption and potassium excretion.
Triamterene is a potassium-sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, reducing sodium reabsorption and potassium excretion.
5 mg orally once daily, increased to 10 mg if needed; maximum 20 mg/day.
100-300 mg orally once daily; maximum 300 mg/day.
None Documented
None Documented
Terminal half-life 6-9 hours; prolonged in renal impairment (up to 20 hours) and in heart failure
Clinical Note
moderateTriamterene + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene."
Clinical Note
moderateTriamterene + Acetyldigitoxin
Terminal elimination half-life is approximately 1.5 to 2 hours. However, in patients with hepatic cirrhosis, half-life may be prolonged up to 4 hours; in renal impairment, half-life can extend significantly (up to 10 hours) due to reduced renal clearance.
Renal: 80-90% as unchanged drug; biliary/fecal: <5%
Approximately 50% of an oral dose is excreted unchanged in urine; about 20% is excreted as metabolites (mainly hydroxytriamterene sulfate conjugate) in urine; biliary/fecal excretion accounts for less than 10%.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene."